Table 1.

Selected Base Case Input Parameters in an Analysis of Long-Acting Cabotegravir-Rilpivirine With Wraparound Services Compared With Oral Integrase Inhibitor–Based Antiretroviral Therapy With or Without Wraparound Services for Nonsuppressed People With HIV Experiencing Adherence Barriers

Parameter	Value		Source
Cohort characteristics			Derived from [15]
Age, y, mean (SD)	47 (10)
Sex at birth, male/female %	90/10
CD4 count, cells/µL, mean (SD)	150 (75)
Adherence distribution on oral INSTI-based ART	Without WS	With WS	Derived from [7]
Mean, %	65	67
Proportion with MPR 50%–66%	63	32
Proportion with MPR 66%–70%	35	57
Proportion with MPR 70%–95%	2	10
HIV RNA suppression at 3 mo after ART initiation
INSTI, INSTI/WS	13%	28%	[7, 21–25]
CAB-RPV/WS	NA	60%	[15]
Subsequent rates of viremia, per 100 PY
INSTI, INSTI/WS	7.37	7.19	[7, 21–25]
CAB-RPV/WS	NA	3.29	[26]
Engagement in care
Loss to follow-up rate, per 100 PY, mean (SD)	28 (2)	16 (1)	Derived from [7, 27]
Return to care rate, per 100 PY	18	18	[28]
RMR of non-HIV-related mortality vs the general population	9	9	[29]

Abbreviations: ART, antiretroviral therapy; CAB-RPV/WS, long-acting injectable cabotegravir-rilpivirine with wraparound services; HIV, human immunodeficiency virus; INSTI, oral integrase inhibitor–based antiretroviral therapy; INSTI/WS, oral integrase inhibitor–based antiretroviral therapy with wraparound services; MPR, medication possession ratio; NA, not applicable; PY, person-years; RMR, relative mortality ratio; SD, standard deviation; WS, wraparound services.